Skip to main content
Top
Published in: Journal of General Internal Medicine 8/2008

01-08-2008 | Original Article

Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?

Authors: Kathryn M. Ryder, MD, MS, Steven R. Cummings, MD, Lisa Palermo, MS, Suzanne Satterfield, MD, DrPH, Douglas C. Bauer, MD, Adrianne C. Feldstein, MD, MS, John T. Schousboe, MD, MS, Ann V. Schwartz, PhD, Kristine Ensrud, MD, MPH, for the Fracture Intervention Trial Research Group

Published in: Journal of General Internal Medicine | Issue 8/2008

Login to get access

Abstract

Background

Postmenopausal women with a prior fracture have an increased risk for future fracture. Whether a history of non-vertebral fracture defines a group of women with low bone mass but without osteoporosis for whom alendronate would prevent new non-vertebral fracture is not known.

Subjects and Methods

Secondary analysis of data from the Fracture Intervention Trial (FIT). Of 2,785 postmenopausal women with a T-score at the femoral neck between −1 and −2.5 and without prevalent radiographic vertebral deformity, 880 (31.6%) reported experiencing a fracture after 45 years of age. Women were randomized to placebo or alendronate (5 mg/day years for the first 2 years and 10 mg/day thereafter) and were followed for an average of 4.2 ± 0.5 years. Incident non-vertebral fractures were confirmed by x-rays and radiology reports.

Results

In the placebo arm, a self-report of prior fracture identified women with a 1.5-fold (hazard ratio [RH] 1.46, 95% C.I. 1.04–2.04) increased risk for incident non-vertebral fracture. However, there was no evidence that the effect of alendronate differed across subgroups of women with (RH 1.26 for alendronate vs placebo, 95% C.I. 0.89–1.79) and without prior fracture (RH 1.02 for alendronate vs placebo, 95% C.I. 0.76–1.38; P = 0.37 for interaction).

Conclusion

Assessing a clinical risk factor, prior non-vertebral fracture, did not identify women with low bone mass for whom alendronate reduced future non-vertebral fracture risk.
Literature
1.
go back to reference Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–8.PubMedCrossRef Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–8.PubMedCrossRef
2.
go back to reference Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–93.PubMedCrossRef Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–93.PubMedCrossRef
3.
go back to reference Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community. J Bone Miner Res. 1998;13:1337–42.PubMedCrossRef Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community. J Bone Miner Res. 1998;13:1337–42.PubMedCrossRef
4.
go back to reference Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202.PubMedCrossRef Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202.PubMedCrossRef
5.
go back to reference Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites and risk of fractures of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947–54.PubMedCrossRef Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites and risk of fractures of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947–54.PubMedCrossRef
6.
go back to reference Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–12.PubMedCrossRef Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–12.PubMedCrossRef
7.
go back to reference Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fracture have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.PubMedCrossRef Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fracture have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.PubMedCrossRef
8.
go back to reference Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767–73.PubMedCrossRef Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767–73.PubMedCrossRef
9.
go back to reference Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111–5.PubMed Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111–5.PubMed
10.
go back to reference Dargent-Molina P, Faviier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145–9.PubMedCrossRef Dargent-Molina P, Faviier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145–9.PubMedCrossRef
11.
go back to reference National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998. National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998.
12.
go back to reference American Association of Clinical Endocrinology. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates from 2003. Endocrine Pract. 2003;9:544–64. American Association of Clinical Endocrinology. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates from 2003. Endocrine Pract. 2003;9:544–64.
13.
go back to reference Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int. 2007;18:761–70.PubMedCrossRef Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int. 2007;18:761–70.PubMedCrossRef
14.
go back to reference Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med. 1997;157:2614–7. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med. 1997;157:2614–7.
15.
go back to reference Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80:343–9.PubMedCrossRef Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80:343–9.PubMedCrossRef
16.
go back to reference Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA. 1998;280:2077–82.PubMedCrossRef Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA. 1998;280:2077–82.PubMedCrossRef
17.
go back to reference Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142:734–41.PubMed Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142:734–41.PubMed
18.
go back to reference Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis Int. 2005;16:1883–93.CrossRef Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis Int. 2005;16:1883–93.CrossRef
19.
go back to reference McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–40.PubMedCrossRef McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–40.PubMedCrossRef
20.
go back to reference Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813–9.PubMedCrossRef Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813–9.PubMedCrossRef
21.
go back to reference Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15:175–9.PubMedCrossRef Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15:175–9.PubMedCrossRef
22.
go back to reference Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164:1113–20.PubMedCrossRef Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164:1113–20.PubMedCrossRef
23.
go back to reference Black DM, Reiss TF, Nevitt MC, et al. Design of the fracture intervention trial. Osteoporos Int. 1993;3(suppl):3S29–S39.PubMedCrossRef Black DM, Reiss TF, Nevitt MC, et al. Design of the fracture intervention trial. Osteoporos Int. 1993;3(suppl):3S29–S39.PubMedCrossRef
24.
go back to reference Genant HK, Jergas M, van Kuijk C, eds. Vertebral Fracture in Osteoporosis. San Francisco, Calif: Radiology Research and Educational Foundation; 1995:131–147. Genant HK, Jergas M, van Kuijk C, eds. Vertebral Fracture in Osteoporosis. San Francisco, Calif: Radiology Research and Educational Foundation; 1995:131–147.
25.
go back to reference Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344–52.PubMedCrossRef Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344–52.PubMedCrossRef
26.
go back to reference Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91.PubMedCrossRef Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91.PubMedCrossRef
27.
go back to reference Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.CrossRef Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.CrossRef
28.
go back to reference Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.PubMedCrossRef
29.
go back to reference Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. the Women’s Health Initiative Randomized Trial. JAMA. 2003;290:1729–38.PubMedCrossRef Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. the Women’s Health Initiative Randomized Trial. JAMA. 2003;290:1729–38.PubMedCrossRef
30.
go back to reference Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef
31.
go back to reference Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.PubMedCrossRef Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.PubMedCrossRef
32.
go back to reference Gallacher SJ, Gallagher AP, McQuillian C, et al. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int. 2007;18:185–92.PubMedCrossRef Gallacher SJ, Gallagher AP, McQuillian C, et al. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int. 2007;18:185–92.PubMedCrossRef
33.
go back to reference Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res. 2006;21:292–9.PubMedCrossRef Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res. 2006;21:292–9.PubMedCrossRef
34.
go back to reference Schousboe JT, Bauer DC, Nyman KA, et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int. 2007;18:201–10.PubMedCrossRef Schousboe JT, Bauer DC, Nyman KA, et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int. 2007;18:201–10.PubMedCrossRef
35.
go back to reference Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol. 1992;135:490–9.PubMed Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol. 1992;135:490–9.PubMed
36.
go back to reference Hundrup YA, Hoidrop S, Obel EB, Rasmussen NK. The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register. Scand J Pub Health. 2004;32:136–43.CrossRef Hundrup YA, Hoidrop S, Obel EB, Rasmussen NK. The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register. Scand J Pub Health. 2004;32:136–43.CrossRef
37.
go back to reference Ivers RQ, Cummings RG, Mitchell P, Peduto AJ. The accuracy of self-reported fractures in older people. J Clin Epidemiol. 2002;55:452–7.PubMedCrossRef Ivers RQ, Cummings RG, Mitchell P, Peduto AJ. The accuracy of self-reported fractures in older people. J Clin Epidemiol. 2002;55:452–7.PubMedCrossRef
Metadata
Title
Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?
Authors
Kathryn M. Ryder, MD, MS
Steven R. Cummings, MD
Lisa Palermo, MS
Suzanne Satterfield, MD, DrPH
Douglas C. Bauer, MD
Adrianne C. Feldstein, MD, MS
John T. Schousboe, MD, MS
Ann V. Schwartz, PhD
Kristine Ensrud, MD, MPH
for the Fracture Intervention Trial Research Group
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 8/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0622-0

Other articles of this Issue 8/2008

Journal of General Internal Medicine 8/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.